Novartis CEO-Designate Set To Bring More Automation To Drug Discovery

Vasant Narasimhan, who is replacing Joseph Jimenez as Novartis' CEO next year, is an advocate of automation and artificial intelligence in future drug discovery.

Relay
Novartis CEO Joe Jimenez Will Hand Over To Vas Narasimhan On Feb 1, 2018 • Source: Shutterstock

With Novartis AG's root-to-branch revamp a reality, its American CEO Joseph Jimenez is passing the leadership baton to the Swiss group's chief medical officer Vasant Narasimhan – another American who has been increasingly at the center of its drug development and commercialization strategy and who is a big proponent of automation and artificial intelligence in future discovery.

News of Jimenez's departure - effective Feb. 1, 2018 - came as a surprise to the industry, and comes after...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Executives On The Move

Executives On The Move: Three New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Trogenix and Quetzal Therapeutics, plus Synendos Therapeutics gains a new CMO from Roche.

Executives On The Move: Five New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Ascentage Pharma, Inventiva and Brenig Therapeutics, plus five companies get new CFOs.

Executives On The Move: New CEOs At Outlook Therapeutics And Peptomyc

Recent moves in the industry include C-suite changes at Essential Pharma, plus Kyverna Therapeutics gets new chief financial officer from Alector.

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By 

Joshi joins the parent company of Citeline, which houses flagship publications Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.

More from Leadership

Chief Strategist O’Hara On Novavax’s Partnership-Focused Approach

 
• By 

A deal last year with Sanofi relieved Novavax of commercial costs for the COVID-19 vaccine Nuvaxovid, allowing the company to focus on R&D and finding partners for its other vaccines.

Pharma Gets A Compatriot At CDER With Tidmarsh Appointment To Top Spot

 

Drug manufacturers may find comfort in the appointment of former biotech CEO and entrepreneur George Tidmarsh to lead the FDA’s Center for Drug Evaluation and Research.

Insmed’s New R&D Site Focused On ‘Synthetic Rescue’

 

A new small-molecule approach to turning on beneficial genes to counteract disease-causing mutations is being pioneered by Insmed’s UK-based scientists.